New York State Teachers Retirement System Sells 3,100 Shares of Inogen Inc (INGN)
New York State Teachers Retirement System lowered its position in Inogen Inc (NASDAQ:INGN) by 9.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,672 shares of the medical technology company’s stock after selling 3,100 shares during the period. New York State Teachers Retirement System’s holdings in Inogen were worth $1,926,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in INGN. Royal Bank of Canada increased its stake in Inogen by 946.1% in the second quarter. Royal Bank of Canada now owns 257,941 shares of the medical technology company’s stock worth $12,926,000 after buying an additional 233,283 shares in the last quarter. Eqis Capital Management Inc. bought a new stake in Inogen during the third quarter worth approximately $349,000. Capstone Asset Management Co. increased its stake in Inogen by 4.6% in the third quarter. Capstone Asset Management Co. now owns 4,780 shares of the medical technology company’s stock worth $286,000 after buying an additional 210 shares in the last quarter. Nationwide Fund Advisors increased its stake in Inogen by 2.6% in the third quarter. Nationwide Fund Advisors now owns 79,109 shares of the medical technology company’s stock worth $4,739,000 after buying an additional 1,970 shares in the last quarter. Finally, Lebenthal Lisanti Capital Growth LLC increased its stake in Inogen by 40.8% in the third quarter. Lebenthal Lisanti Capital Growth LLC now owns 23,637 shares of the medical technology company’s stock worth $1,416,000 after buying an additional 6,850 shares in the last quarter.
Shares of Inogen Inc (NASDAQ:INGN) opened at 76.44 on Tuesday. The stock has a market cap of $1.57 billion, a P/E ratio of 78.80 and a beta of 1.07. Inogen Inc has a one year low of $39.57 and a one year high of $79.94. The firm has a 50 day moving average of $69.41 and a 200 day moving average of $63.62.
Your IP Address:
A number of analysts recently commented on INGN shares. Needham & Company LLC started coverage on shares of Inogen in a report on Thursday, January 19th. They set a “strong-buy” rating on the stock. Zacks Investment Research downgraded shares of Inogen from a “strong-buy” rating to a “hold” rating in a report on Monday, February 6th. Stifel Nicolaus boosted their price objective on shares of Inogen to $65.00 in a report on Wednesday, March 1st. JPMorgan Chase & Co. set a $78.00 price objective on shares of Inogen and gave the stock a “buy” rating in a report on Wednesday, March 1st. Finally, TheStreet raised shares of Inogen from a “c” rating to a “b-” rating in a report on Tuesday, February 28th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Inogen presently has a consensus rating of “Buy” and a consensus price target of $68.17.
In other news, EVP Matt Scribner sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $73.85, for a total value of $184,625.00. Following the transaction, the executive vice president now directly owns 4,833 shares in the company, valued at approximately $356,917.05. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Raymond Huggenberger sold 5,680 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $63.96, for a total transaction of $363,292.80. Following the completion of the transaction, the chief executive officer now owns 12,488 shares in the company, valued at $798,732.48. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 51,358 shares of company stock worth $3,394,316. Insiders own 5.18% of the company’s stock.
Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.
Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.